Pipe SW - Search Results

1

A Cornucopia of Therapies under Study for Hemophilia.

Pierce GF, Pipe SW. Pierce GF, et al. Among authors: pipe sw. Mol Ther. 2017 Nov 1;25(11):2429-2430. doi: 10.1016/j.ymthe.2017.10.009. Epub 2017 Oct 19. Mol Ther. 2017. PMID: 29055619 Free PMC article. No abstract available.

2

Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment.

Pierce GF, Lillicrap D, Pipe SW, Vandendriessche T. Pierce GF, et al. Among authors: pipe sw. J Thromb Haemost. 2007 May;5(5):901-6. doi: 10.1111/j.1538-7836.2007.02410.x. J Thromb Haemost. 2007. PMID: 17459005 Free article. Review.

3

The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene.

Chen L, Zhu F, Li J, Lu H, Jiang H, Sarkar R, Arruda VR, Wang J, Zhao J, Pierce GF, Ding Q, Wang X, Wang H, Pipe SW, Liu XQ, Xiao X, Camire RM, Xiao W. Chen L, et al. Among authors: pipe sw. Mol Ther. 2007 Oct;15(10):1856-62. doi: 10.1038/sj.mt.6300268. Epub 2007 Jul 24. Mol Ther. 2007. PMID: 17653101 Free PMC article.

4

Correction of murine hemophilia A and immunological differences of factor VIII variants delivered by helper-dependent adenoviral vectors.

Cerullo V, Seiler MP, Mane V, Cela R, Clarke C, Kaufman RJ, Pipe SW, Lee B. Cerullo V, et al. Among authors: pipe sw. Mol Ther. 2007 Dec;15(12):2080-7. doi: 10.1038/sj.mt.6300308. Epub 2007 Sep 11. Mol Ther. 2007. PMID: 17848960 Free article.

5

Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping.

Ogata K, Selvaraj SR, Miao HZ, Pipe SW. Ogata K, et al. Among authors: pipe sw. J Thromb Haemost. 2011 Jun;9(6):1183-90. doi: 10.1111/j.1538-7836.2011.04268.x. J Thromb Haemost. 2011. PMID: 21645226 Free PMC article.

6

New therapies for hemophilia.

Pipe SW. Pipe SW. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):650-656. doi: 10.1182/asheducation-2016.1.650. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913542 Free PMC article. Review.

7

Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies.

Pierce GF, Ragni MV, van den Berg HM, Weill A, O'Mahony B, Skinner MW, Pipe SW. Pierce GF, et al. Among authors: pipe sw. Haemophilia. 2017 Sep;23(5):643-644. doi: 10.1111/hae.13313. Epub 2017 Aug 17. Haemophilia. 2017. PMID: 28833947 No abstract available.

8

Gene therapy for hemophilia.

Pipe SW. Pipe SW. Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26865. Epub 2017 Oct 27. Pediatr Blood Cancer. 2018. PMID: 29077262 Free article. Review.

9

Bioengineered molecules for the management of haemophilia: Promise and remaining challenges.

Pipe SW. Pipe SW. Haemophilia. 2018 May;24 Suppl 6:68-75. doi: 10.1111/hae.13507. Haemophilia. 2018. PMID: 29878662 Free article. Review.

10

New therapies for hemophilia.

Weyand AC, Pipe SW. Weyand AC, et al. Among authors: pipe sw. Blood. 2019 Jan 31;133(5):389-398. doi: 10.1182/blood-2018-08-872291. Epub 2018 Dec 17. Blood. 2019. PMID: 30559264 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

170 results

Search Page

Filters